Nizatidine

Nizatidine is a histamine H₂ receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.<ref name="pmid2567957">Template:Cite journal</ref>

It was patented in 1980 and approved for medical use in 1988.<ref name="FDA approval">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>Template:Cite book</ref> It was developed by Eli Lilly.

Medical use

{{#invoke:Labelled list hatnote|labelledList|Main article|Main articles|Main page|Main pages}} Nizatidine is used to treat duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease (GERD/GORD), and to prevent stress ulcers.<ref name=LiverTox>Template:Cite book</ref>

Adverse effects

Side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache, and muscle aches.<ref name=LiverTox/>

History and development

Nizatidine was developed by Eli Lilly, and was first marketed in 1988.<ref name="FDA approval" /> It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to Reliant Pharmaceuticals.<ref name="encyclopedia">Template:Cite encyclopedia</ref> Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the U.S. Food and Drug Administration (FDA).<ref name="reliant2004">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> However, a year later, they sold rights of the Axid Oral Solution (including the issued patent<ref>Template:Cite patent</ref> protecting the product) to Braintree Laboratories.<ref name="reliant2005">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Society and culture

Brand names

Brand names include Tazac and Axid.